InnovaTV 301/ENGOT-cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

Proceedings of the Biennial Meeting of Asian Society of Gynecologic Oncology(2024)

引用 0|浏览15
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要